Gene · 3205
Papers4,255
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 4,255
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis. | Blood Neoplasia | 2025 | 40979070 | PubTator, text mining | PubMed |
| Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. | Blood Neoplasia | 2025 | 40979068 | PubTator, text mining | PubMed |
| The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. | Clin Cancer Res | 2025 | 40970773 | PubTator, text mining | PubMed |
| Ribosome heterogeneity arising from common and rare rRNA sequence variants affects diverse human phenotypes. | medRxiv | 2025 | 40950416 | PubTator, text mining | PubMed |
| The MLLT3 YEATS domain is a dual reader of histone marks (H3K9/18/27ac/cr) and ncRNA (7SK), linking epigenetic and RNA signaling to regulate hematopoiesis. | bioRxiv | 2025 | 40950097 | PubTator, text mining | PubMed |
| Development and validation of a methylation-specific droplet digital PCR multiplex for lung cancer detection. | Sci Rep | 2025 | 40897746 | PubTator, text mining | PubMed |
| A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model. | Br J Haematol | 2025 | 40884014 | PubTator, text mining | PubMed |
| Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study. | PLoS One | 2025 | 40880391 | PubTator, text mining | PubMed |
| Signature of leukemia stem cell death pattern predicts prognosis and therapeutic response of acute myeloid leukemia patients. | Sci Rep | 2025 | 40866598 | PubTator, text mining | PubMed |
| The roles of non-coding RNAs (ncRNAs) in the function of leukemic stem cells (LSCs): a comprehensive review. | Discov Oncol | 2025 | 40853607 | PubTator, text mining | PubMed |
| Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities. | Mol Cancer | 2025 | 40849651 | PubTator, text mining | PubMed |
| Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia. | Br J Pharmacol | 2025 | 40831365 | PubTator, text mining | PubMed |
| Machine learning identification of molecular targets for medulloblastoma subgroups using microarray gene fingerprint analysis. | Comput Struct Biotechnol J | 2025 | 40808800 | PubTator, text mining | PubMed |
| Similar Genetic Routes Are Independently Targeted for Mimetic Color Convergence in Bumble Bees. | Mol Biol Evol | 2025 | 40795243 | PubTator, text mining | PubMed |
| Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells. | bioRxiv | 2025 | 40791540 | PubTator, text mining | PubMed |
| The myeloid transcription factor Elf1 regulates genes with function in innate immunity. | Exp Hematol | 2025 | 40780499 | PubTator, text mining | PubMed |
| [Molecular mechanism and therapeutic targeting of MLL-rearranged leukemia]. | Rinsho Ketsueki | 2025 | 40769927 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia. | Invest New Drugs | 2025 | 40758222 | PubTator, text mining | PubMed |
| Evaluation of HOTAIRM1, miR-196b, and HOXA9 as Oncogenic Markers in Patients with Acute Myeloblastic Leukemia. | Iran J Pathol | 2025 | 40746924 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3205/papers?page=5